Ascensia Diabetes Care names Peter Bodlund as CEO

Ascensia Diabetes Care announced Peter Bodlund will become President and Chief Executive Officer effective April 1, 2026. Bodlund currently serves as Chief Operating Officer of the diabetes care company.

Bodlund will succeed Koichiro Sato, who will continue as Chief Operating Officer of PHC Group and Head of PHC Group's Diabetes Management business. Bodlund will also be appointed a Corporate Officer of PHC Group.

The leadership transition comes as Ascensia continues operations in diabetes management technology, including blood glucose monitoring systems. Ascensia is a subsidiary of PHC Holdings Corporation (TSE: 6523).

"Peter brings proven strategic and operational leadership experience, with a clear focus on results, and I am confident he will lead Ascensia effectively as President and Chief Executive Officer," Sato said in a statement.

Ascensia manufactures the CONTOUR portfolio of blood glucose monitoring systems and sells products in more than 100 countries. The company operates direct commercial organizations in 29 countries worldwide.

PHC Holdings reported consolidated net sales of JPY 361.6 billion in fiscal year 2024, with global distribution in more than 125 countries and regions. The company's subsidiaries include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex Corporation, and Mediford Corporation.

You May Also Be Interested In

• AVAX One CFO departs, controller promoted to chief accounting officer
• XTI Aerospace CEO resigns amid internal review and late SEC filing
• Merit Medical names new EVP of global operations as COO prepares to exit